Search

Learn about some of the most important advances in cancer treatment and clinical trials at MSK in 2024.

… Tuesday, December 17, 2024 Doctors at Memorial Sloan Kettering Cancer Center (MSK) pioneered advances in a variety of cancer treatments in 2024 — including new surgical techniques, innovative cancer vaccines, drugs to boost radiation therapy’s effectiveness, and novel tools to diagnose and detect cancer

Memorial Sloan Kettering Cancer Center (MSK) molecular pharmacologist Daniel Heller, PhD, and colleagues have identified a new strategy to target drugs specifically to cancer sites, including metastatic tumors. The approach involves nanoparticles designed to mimic a mechanism that tumors themselves use to metastasize throughout the body. This work, which will be featured on the cover of the June 29 issue of Science Translational Medicine, was applicable across a wide range of tumor and drug types and can potentially be applied to other conditions including vascular and autoimmune diseases.

… Wednesday, June 29, 2016 Memorial Sloan Kettering Cancer Center (MSK) molecular pharmacologist Daniel Heller, PhD, and colleagues have identified a new strategy to target drugs specifically to cancer sites, including metastatic tumors. The approach involves nanoparticles designed to mimic a mechanism

A recent study found that the cell lines most commonly used for research on ovarian cancer are not the most suitable.

… Monday, August 26, 2013 Summary A recent study found that the cell lines most commonly used for research on ovarian cancer are not the most suitable. Research done in cancer cell lines – colonies of cells that derive from a patient’s tumor and can be grown in culture indefinitely – has revealed important

The U.S. Food and Drug Administration (FDA) approved 11 cancer drugs in 2024 based on significant contributions from MSK researchers.

… Friday, June 6, 2025 In 2024, the U.S. Food and Drug Administration (FDA) approved 11 drugs based on clinical trials in which MSK played a pivotal role.  These approvals expand treatment options for a range of cancers, including subtypes of brain, lung, breast, thyroid, and colorectal cancer, and span

Pediatric oncologist Julia Glade Bender talks about the challenges of treating rare childhood cancers and how personalized medicine is leading to better therapies for tumors that are especially hard to treat.

… Friday, September 20, 2019 Summary In this Q & A, pediatric oncologist Julia Glade Bender talks about how childhood cancers and adult cancers are different, and the promise of personalized medicine to treat tumors that are especially challenging. Julia Glade Bender is a pediatric oncologist and Vice

Information gleaned from a liquid biopsy may help predict how individual women with advanced breast cancer will respond to certain therapies as well as reveal genetic mutations that can impact prognosis, according to two new studies led by Memorial Sloan Kettering Cancer Center (MSK) Physician-in-Chief José Baselga and physician-scientist Sarat Chandarlapaty. The studies were presented this week at the San Antonio Breast Cancer Symposium.

… Friday, December 11, 2015 Information gleaned from a liquid biopsy may help predict how individual women with advanced breast cancer will respond to certain therapies as well as reveal genetic mutations that can impact prognosis, according to two new studies led by Memorial Sloan Kettering Cancer Center

The SNO Lifetime Achievement Award is given annually to a meritorious individual who has made significant contributions in neuro-oncology over their career in clinical care and/or translational or basic research.

… Monday, November 20, 2023 Lisa DeAngelis, MD , Chief Physician Executive and Scott M. and Lisa G. Stuart Chair of Memorial Sloan Kettering Cancer Center (MSK), was awarded the prestigious  Society for Neuro-Oncology (SNO) 2023 Lifetime Achievement Award. The SNO Lifetime Achievement Award is given annually

With the creation of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering sets out to deliver on the promise of personalized medicine by creating better treatment options for all people with cancer.

… Tuesday, May 20, 2014 Summary With the creation of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering sets out to deliver on the promise of personalized medicine by creating better treatment options for all people with cancer. We are thrilled to announce the creation

Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.

… Tuesday, February 22, 2022 Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments: Tomya Watt Named to Crain’s New York Business Notable Black Leaders 2022 List Tomya Watt Tomya Watt , Chief Diversity Officer and Vice President of Talent Acquisition and Mobility,

Physicians and scientists from Memorial Sloan Kettering Cancer Center (MSK) will join oncology experts and members of the global cancer research community to present the latest advances in cancer during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31–June 4, in Chicago.

… Thursday, May 23, 2024 Physicians and scientists from Memorial Sloan Kettering Cancer Center (MSK) will join oncology experts and members of the global cancer research community to present the latest advances in cancer during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31